{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"18"}]}],"title":"TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"17"}]}],"title":"TEAE related to Pomalidomide"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"18"}]}],"title":"TEAE related to Dexamethasone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"18"}]}],"title":"TEAE related to Daratumumab"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Metastatic Malignant Melanoma"}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.","groups":[{"description":"(Pomalidomide + low dose Dexamethasone) in participants with 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old).","id":"OG000","title":"Cohort A"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG001","title":"Cohort B"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in Japanese participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG002","title":"Cohort C"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose until 28 days post last dose (Up to 120 months)","title":"Number of Participants With Treatment Emergent Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}